

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 9/86, 15/00, 15/09, 15/63, 15/70, 15/74, 1/20, C12P 13/04, 13/06, C07H 21/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/58449</b> <b>(43) International Publication Date:</b> 5 October 2000 (05.10.00)
<b>(21) International Application Number:</b> PCT/US00/08159 <b>(22) International Filing Date:</b> 28 March 2000 (28.03.00)  <b>(30) Priority Data:</b> 60/126,923 29 March 1999 (29.03.99) US 60/157,427 4 October 1999 (04.10.99) US 09/497,585 3 February 2000 (03.02.00) US  <b>(71) Applicants:</b> CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1200 East California Boulevard, Pasadena, CA 92115 (US). DEGUSSA-HÜLS AG [DE/DE]; Rodenbacher Chaussee 4, D-63457 Hanau-Wolfgang (DE).  <b>(72) Inventors:</b> ARNOLD, Frances, H.; 629 S. Grand Avenue, Pasadena, CA 91105 (US). MAY, Oliver; Fellbacherstrasse 41, D-70327 Stuttgart (DE). DRAUZ, Karlheinz; Zur Marienruhe 13, D-63579 Freigericht (DE). BOMMARIUS, Andreas; Waidmann Strasse 7, D-60596 Frankfurt am Main (DE).  <b>(74) Agents:</b> OLDENKAMP, David, J. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 3800, 2029 Century Park East, Los Angeles, CA 90067 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> HYDANTOINASE VARIANTS WITH IMPROVED PROPERTIES AND THEIR USE FOR THE PRODUCTION OF AMINO ACIDS		
<b>(57) Abstract</b>  Hydantoinase enzymes which are mutants of a previously isolated hydantoinase having the amino acid SEQ. ID. NO. 2. The mutants include amino acid substitutions at positions (95, 154, 180, 251 and/or 255) of the wild type hydantoinase (SEQ. ID. NO. 2). The mutant hydantoinases, like the parent hydantoinase, are used in the production of optically pure amino acids.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**HYDANTOINASE VARIANTS WITH IMPROVED PROPERTIES  
AND THEIR USE FOR THE PRODUCTION OF AMINO ACIDS**

**BACKGROUND OF THE INVENTION**

1. Field of the Invention

The present invention relates generally to hydantoinases. More particularly, the present invention involves the discovery of a number of modified hydantoinases which exhibit improved enzymatic properties relative to previously isolated hydantoinases and their use in whole-cell catalysts to manufacture amino acids.

2. Description of Related Art

Hydantoin hydrolyzing enzymes, which will be referred here as 'hydantoinases', comprise a diverse class of enzymes having a wide range of specificities and biological functions. Some hydantoinases for example play an essential role in the reductive pathway of pyrimidine degradation (dihydropyrimidinases, EC 3.5.2.2) whereas others catalyze reactions in the purine degradation pathway (allantoinases, EC 3.5.2.5). Despite their functional diversity hydantoinases show significant sequence similarities and belong to a superfamily of amidohydrolases related to ureases as described by Holm, L., and Sander, C. (1997) An evolutionary treasure: Unification of a broad set of amidohydrolases related to ureases, *Proteins* **28**:72-82; The alignment of sequences from the different hydantoinases was used to identify conserved residues that are important for catalytic function as described by May, O., Habenicht, A., Mattes, R., Syltatk, C. and Siemann, M. (1998) Molecular Evolution of Hydantoinases, *Biol. Chem.* **379**:743-747; and Kim, G.J. and Kim, H.S. (1998) Identification of the structural similarity in the functionally related amidohydrolases acting on the cyclic amide ring. *Biochem. J.* **330**:295-302. Despite this knowledge that allows to identify equivalent amino acid residues of the different hydantoinases, knowledge about the function of other amino acid residues is limited. So far, no X-ray structure of hydantoinases was reported.

An important property of hydantoinases is their enantioselectivity which makes them valuable for the production of optically pure D- or L-amino acids. A detailed background of hydantoinases is provided in the published doctoral thesis of Oliver May entitled "The Hydantoinase from *Arthrobacter aurescens*

DSM 3745 and its Relation to other Hydantoinases" (Institut fuer Bioverfahrenstechnik, Lehrstuhl Physiologische Mikrobiologie, Universitaet Stuttgart- 1998).

5 In view of the importance of hydantoinases to the production of optically pure amino acids, there has been a concentrated effort to develop modified enzymes which have improved properties with respect to amino acid production. As a result of this effort, a number of microorganisms have been isolated and identified which produce hydantoinases with desirable enzymatic properties. U.S. Pat. No. 5,516,660 discloses microorganisms identified as 10 DSM7329 and DSM 7330 which produce hydantoinases that are capable of producing L-alpha-amino acids from D-, L- and/or D,L-5-monosubstituted hydantoins. In U.S. Pat. No. 5,714,355, a mutant of the DSM 7330 microorganism is disclosed which has greater enzymatic activity than the parent organism by a factor of up to 2.7. The mutant (DSM 9771) was 15 obtained by cultivating the parent DSM 7330 organism under selective pressure using L-carbamoylmethionine (L-CAM) as the sole source of nitrogen. Although the hydantoinases produced by the above-mentioned microorganisms are well-suited for at least some of their intended purposes, there still is a continuing need to develop new enzymes which exhibit even more desirable 20 hydantoinase activity. In particular, there is a need to improve enantioselectivity as well as catalytic activity.

#### SUMMARY OF THE INVENTION

25 In accordance with the present invention, modified hydantoinases are provided which have enhanced enzymatic properties (better whole-cell catalysts) with respect to the hydantoinase produced by the microorganism DSM 9771 which is identified in U.S. Pat. No. 5,714,355. The DSM 9771 hydantoinase has an amino acid sequence which includes numbered positions ranging sequentially from 1 to 458 (SEQ. ID. NO. 2).

30 It was discovered that substitution of amino acids at one or more specific amino acid positions within the DSM 9771 enzyme resulted in the formation of enzymes having enhanced properties with respect to activity and enantioselectivity. The specific amino acid position numbers at which substitutions are made to achieve the modified hydantoinase enzymes in 35 accordance with the present invention are positions Nos. 95, 154, 180, 251 and 255. As a further feature of the invention, specific amino acid substitutions at the various positions are identified to provide specific types of

modified hydantoinases. The specific amino acid substitutions include I95F, I95L, V154A, V180A, Q251R and V255A. One or more of these specific substitutions were found to enhance the enzymatic activity and change the enantioselectivity of the "wild type" DSM 9771 hydantoinase. These changed enzyme properties were found to contribute to a significantly improved hydantoinase process by reducing the accumulation of the wrong enantiomer of the N-carbamoyl-amino acid.

Six specific modified hydantoinases are disclosed which have one or more of the above amino acid substitutions. The amino acid sequences for these modified hydantoinases are set forth in SEQ. ID. NOS. 4, 6, 8, 10, 12 and 14. These modified hydantoinases are also identified throughout the specification as 1CG7, 11DH7, 1BF7, 19AG11, 22CG2 and Q2H4, respectively.

It was further discovered that hydantoinases evolved for activity and/or enantioselectivity can dramatically improve the production of amino acids (i.e., L-methionine) using a whole cell catalyst comprising an evolved hydantoinase in addition to at least a carbamoylase.

The above discussed and many other features and attendant advantages of the present invention will become better understood by reference to the following detailed description when taken in conjunction with the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the restriction map of the vector used for expression of the hydantoinase gene (hyuH) from *Arthrobacter sp.* DSM9771.

FIG. 2 is a chromatogram showing the results of the separation of N-carbamoyl-methionine enantiomers produced by mutants Q2H4, 11DH7 and 1CG7 as compared to the DSM 9771 hydantoinase.

FIG. 3 is a chart which depicts the relative improvements in enzymatic activity and enantioselectivity which is provided by the mutant enzymes of the present invention with respect to the DSM 9771 hydantoinase (**W**).

FIG. 4 is a chart which shows enzymatic activity of different *Arthrobacter* strains and mutant Q2H4 of the present invention.

FIG. 5 is two charts showing the time course of the hydrolysis of 100 mM D,L-MTEH in 0.1M Tris pH 7.8, 37°C with 8mg cell dry mass of **A)** *E.coli* JM109 (pOM20/pOM21) (wildtype pathway) and **B)** *E.coli* JM109 (pOM22/pOM21) (pathway with evolved hydantoinase from Q2H4).

FIG. 6 is a chart showing a comparison of the hydrolysis of 100 mM D,L-MTEH in 0.9% (w/v) NaCl, 1mM MnCl<sub>2</sub>, pH 7.8 with 25g/l *E.coli* JM109 (pOM20, pOM21) and *E.coli* JM109 (pOM21, pOM23) after 1 hour reaction time.

#### DETAILED DESCRIPTION OF THE INVENTION

The modified hydantoinases in accordance with the present invention were produced, identified and isolated using random mutagenesis procedures of the type described in U.S. Pat. Nos. 5,316,935 and 5,906,930. Random mutagenesis protocols, which are also known as directed evolution procedures, are also described in Kuchner, O., Arnold, F.H. (1997) Directed Evolution of Enzyme Catalysts, *TIBTECH* 15:523-530; Chen, K. and Arnold F. (1991). Enzyme engineering for nonaqueous solvents—random mutagenesis to enhance activity of subtilisin E in polar organic media, *Bio/Technology* 9:1073-1077; Chen, K. and Arnold, F. (1993) Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide, *Proc. Natl. Acad. Sci. USA* 90:5618-5622; and You, L. and Arnold, F.H. (1996). Directed Evolution of Subtilisin E in *Bacillus Subtilis* to Enhance Total Activity in Aqueous Dimethylformamide, *Protein Engineering*, 9, 77-83.

The random mutagenesis procedure used to identify and isolate the modified hydantoinases followed the same basic procedures as identified above. First, a large number of random mutations in the wild type nucleotide sequence (SEQ. ID. NO. 1) were generated. This library of nucleotide sequences were then used to express a large number of mutated enzymes. The library of mutated hydantoinases was then screened to identify those mutants with enhanced enzymatic activity and changed enantioselectivity.

The step of screening the first library of expressed amino acid sequences to identify desirable variants could have been accomplished using any number of suitable screening techniques which measure desirable enzyme properties. The screening method actually used was a pH-indicator assay which will be described in more detail below.

In accordance with the present invention, four enzymes having enhanced hydantoinase properties were identified as the result of the first round of random mutagenesis of the DSM 9711 nucleotide sequence (SEQ. ID. NO. 1). The first round mutant enzymes are 1CG7, 11DH7, 1BF7 and 19AG11. The nucleotide sequences for these first round mutants are set forth in SEQ. ID. NOS. 3, 5, 7 and 9, respectively. The corresponding amino acid sequences are set forth in SEQ. ID. NOS. 4, 6, 8 and 10, respectively.

A second round of random mutagenesis was conducted in which the 11DH7 nucleotide sequence was randomly mutated to form a second library of mutants. A single mutant (22CG2) was identified which expressed a modified hydantoinase that exhibited desirable enzymatic properties. The 22CG2 enzyme is the same as the 11DH7 enzyme except that the 22CG2 mutant has an amino acid substitution at position 180.

The 22CG2 mutant was subjected to saturation mutagenesis in order to introduce all 20 different amino acids into amino acid position 95. 400 clones were screened and a mutant enzyme with enhanced enzymatic activity and higher (L)-selectivity was identified as Q2H4. The Q2H4 mutant is the same as the 22CG2 mutant except that phenylalanine is substituted for isoleucine at position 95.

As a result of the isolation and identification of the above identified mutants, it was established that improved hydantoinases may be obtained by modifying the DSM 9771 enzyme by substituting amino acids at positions 95, 124, 154, 180, 251 and 255. The substitutions may be made at one or more of the positions. Table 1 sets forth preferred amino acid substitutions.

**Table 1**

Amino Acid Position	Substitution	Abbreviation
95	Ile → Phe	I95F
95	Ile → Leu	I95L
154	Val → Ala	V154A
180	Val → Ala	V180A
251	Gln → Arg	Q251R
255	Val → Ala	V255A

Amino acid substitutions other than those set forth in Table 1 are possible provided that the resulting hydantoinase exhibits desirable enzymatic properties. For example, other suitable amino acid substitutions for isoleucine at position 95 include Gly, Ala, Val, Leu, Phe, Tyr and Trp. For positions 154, 180 and 255, suitable alternative amino acid substitutions for valine include Ala and Gly. Suitable alternative amino acid substitutions at position 251 for glutamine include Arg, Lys and Asn. The amino acid substitutions may be made by saturation mutagenesis followed by screening of clones. The substitutions may also be made by chemical manipulation of the DSM 9711 enzyme or by conventional synthesis of peptides having the desired amino acid substitutions at the desired locations. It should be noted that the above listed amino acid substitutions are intended to be exemplary of preferred alternative substitutions at the various substitution sites. Substitutions of other amino acids are possible provided that the enzymatic activity of the resulting protein is not destroyed. The usefulness of a particular amino acid substitution at positions 95, 154, 180, 251 and 255 can be determined by routine pH screening as described below.

The amino acid substitutions described above may be made at equivalent positions in other hydantoinases. "Other hydantoinases" refers to enzymes that catalyze the hydrolysis of any 5'-mono- or disubstituted hydantoin derivative to yield the derived N-carbamoyl-amino acid and might have between 20 and 100% amino acid sequence identity to the hydantoinase from *Arthrobacter* sp. DSM 9771 which can be determined by sequence alignment algorithm such as BLAST (Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. (1990) "Basic local alignment search tool." *J. Mol. Biol.* **215**:403-410).

Amino acid positions are numbered in a linear order (starting at the start codon) and not according to their functional and structural context. Therefore amino acid residues that contribute in the same way to an enzyme function of different hydantoinases do not necessarily have the same amino acid position number due to deletion or insertion events in the homologous enzyme. "Equivalent positions" of hydantoinases therefore refers to amino acid positions that contribute in the same way to a function (activity or enantio-selectivity) as the amino acids identified in our evolution experiment. If the amino acid sequence identity of different hydantoinases is high, for example higher than 60%, and the amino acid position is located in a conserved region without sequence gaps, equivalent positions can be determined by sequence



alignment using for example the BLAST algorithm. If the amino acid sequence identity is low, for example lower than 60%, and the amino acid position is located in a non-conserved region, or near gaps without being surrounded by regions of conserved amino acids, other methods such as structure alignments can be used if x-ray structures are available (Mizuguchi, K., Go, N., Seeking significance in 3-dimensional protein-structure comparisons. *Cur. Opin. Struc. Biol.* 5:377-382 (1995)). Here, backbone atoms are structurally aligned and equivalent positions can be found based on the relative locations of the amino acid residues of the structures.

An amino acid position that is identified for example by directed evolution to contribute to a specific function can often be occupied by different amino acid residues, not just the one that was identified by random point mutagenesis. Some substitutions will destroy the function, some of them will not change the function, and yet others will improve the function. With known methods, such as site saturation mutagenesis, one can easily identify amino acids that contribute in the same way to a function or even improve it by replacing the found amino acid residue with all possible amino acid residues (Miyazaki, K., Arnold, F., Exploring nonnatural evolutionary pathways by saturation mutagenesis: rapid improvement of protein function. *J. Mol. Evol.* 49:1716-1720). Even non-natural amino acids can be introduced at the identified site using a stop codon and a suppresser tRNA linked to a non-natural amino acid (Bain, J.D., Glabe, C.G., Dix, T.A., Chamberlain, A.R., Diala, E.S., Biosynthetic Site-Specific Incorporation Of A Non-Natural Amino-Acid Into A Polypeptide. *JACS* 111:8013-8014 (1989)).

Six modified hydantoinases in accordance with the present invention are listed in Table 2. Table 2 also lists the amino acid substitutions with respect to the DSM 9771 sequence (SEQ. ID. NO. 2) for each modified enzyme which is identified.

Table 2

Hydantoinase Variant	Amino Acid Substitution
1CG7 (SEQ. ID. NO. 4)	V154A
11DH7 (SEQ. ID. NO. 6)	I95L + Q251R
1BF7 (SEQ. ID. NO. 8)	V255A
19AG11 (SEQ. ID. NO. 10)	I95L
22CG2 (SEQ. ID. NO. 12)	I95L + V180A + Q251R
Q2H4 (SEQ. ID. NO. 14)	I95F + V180A + Q251R

The modified hydantoinases of the present invention may be used in the same manner as other hydantoinases to produce optically pure D- and L-amino acids. For example, see Biocatalytic Production of Amino Acids and Derivatives (Rozzell, J.D. and Wagner, F. eds.) (1992) Hanser Publisher, NY, at pages 75-176, for a description of the use of hydantoinases in the production of optically pure amino acids from DL-5-monosubstituted hydantoins. The general use of hydantoinases is also described in Enzyme catalysis in organic synthesis (Dranz, K. and Waldmann, H. eds.) 1995, VCH-Verlag, Weinheim, at pages 409-431; and Wagner, T. et al. (1996) Production of l-methionine from d,l-5-(2-methylthioethyl) hydantoin by resting cells of a new mutant strain of *Arthrobacter* species DSM 7330, *Journal of Biotechnology* **46**:63-68.

Amino acids referred to in the present invention are all natural or unnatural amino acids, wherein the amino acids are deemed to be a primary amine connected to carboxylic acid group via one intermediate C-atom ( $\alpha$ -C-atom). This C-atom bears only one further residue. Preferred unnatural amino acids are disclosed in DE 19903268.8. Preferred natural amino acids are those mentioned in Beyer-Walter, *Lehrbuch der Organischen Chemie*, 22. Auflage, S. Hirzel Verlag Stuttgart, S.822-827. Among those amino acids presented above alanine, leucine, isoleucine, methionine, valine, tert.-leucine or neopentyl glycine are not preferably transformed in a process utilizing the modified hydantoinase.

To transform hydantoins directly to the amino acids by enzymes it is preferred to use a whole-cell catalyst which includes the hydantoinase of the invention accompanied with a carbamoylase. A hydantoin racemase can also be used in addition to the hydantoinase and carbamoylase.

The hydantoinase can be used within this process either in their free or immobilized form. Also the carbamoylase and hydantoin racemase may be immobilized, too. Techniques to immobilize enzymes are well known to the skilled worker. Preferred methods are mentioned in Bhavender P. Sharma, Lorraine F. Bailey and Ralph A. Messing, Immobilisierte Biomaterialien - Techniken und Anwendungen, Angew. Chem. 1992, 94, 836-852; Dordick et al., J. Am. Chem. Soc. 194, 116, 5009-5010; Okahata et al., Tetrahedron Lett. 1997, 38, 1971-1974; Adlercreutz et al., Biocatalysis 1992, 6, 291-305; Goto et al., Biotechnol. Prog. 1994, 10, 263-268; Kamiya et al., Biotechnol. Prog. 1995, 11, 270-275; Okahata et al., Tibtech, February 1997, 15, 50-54; Fishman et al., Biotechnol. Lett. 1998, 20, 535-538).

The transformation discussed can be conducted in a batch process or continuous manner. Advantageously, an enzyme-membrane-reactor is used as the reaction vessel (Wandrey et al. in Jahrbuch 1998, Verfahrenstechnik und Chemieingenieurwesen, VDI S. 151ff.; Wandrey et al. in Applied Homogeneous Catalysis with Organometallic Compounds, Vol. 2, VCH 1996, S.832 ff.; Kragl et al., Angew. Chem. 1996, 6, 684f.).

A further embodiment of the present invention is directed to a whole cell catalyst comprising a gene encoding for a carbamoylase, an optional racemase and a hydantoinase wherein the hydantoinase is considered to be according to the modified hydantoinase of the invention.

Advantageously, a bacteria is used as a cell, because of high reproduction rates and easy growing conditions to be applied. There are several bacteria known to the skilled worker which can be utilized in this respect. Preferably *E. coli* can be used as the cell and expression system in this regard (Yanisch-Perron et al., Gene (1985), 33, 103-109).

Another aspect of the invention is a process for the production of enantiomerically enriched amino acids, which utilizes a whole cell catalyst according to the invention.

It is further preferred in this respect that amino acids like methionine, threonine, lysine or tert.-leucine are produced by the aid of the whole cell catalyst.

The transformation discussed in this instance can be conducted in a batch process or continuous manner. Advantageously, an enzyme-membrane-reactor is used as the reaction vessel (Wandrey et al. in Jahrbuch 1998, Verfahrenstechnik und Chemieingenieurwesen, VDI S. 151ff.; Wandrey et al. in

Applied Homogeneous Catalysis with Organometallic Compounds, Vol. 2, VCH 1996, S832 ff.; Kragl et al., Angew. Chem. 1996, 6, 684f; DE 19910691.6).

There is a further aspect of the invention, which is directed to a process for the production of a whole cell catalyst of the invention. The process is preferably conducted by using expression vectors pOM17, pOM18, pOM20, pOM22 and/or pOM21. In addition primers of SEQ. NO. 17, SEQ. NO. 18, SEQ. NO. 15 and/or SEQ. NO. 16 are used with regard to the production of the whole cell catalyst.

Examples of Practice are as follows:

#### Example 1

The following example provides additional details regarding the procedures used to identify and isolate the modified hydantoinases in accordance with the present invention.

The hydantoinase from *Arthrobacter* sp. DSM 9771 (U.S. Pat. No. 5,714,355) was cloned by polymerase chain reaction (PCR). The nucleotide sequence was determined and compared to other hydantoinases from closely related *Arthrobacter* strains. The nucleotide and amino acid sequences for the hydantoinase are set forth in SEQ. ID. NOS. 1 and 2, respectively. The cloned enzymes from *Arthrobacter* sp. DSM 9771 share about 97.5% identity based on their nucleotide sequence (corresponding to 7 amino acid changes) with the enzymes from *Arthrobacter aureescens* DSM 3747 and DSM 3745. The enzymes were expressed in *E.coli* JM109 using a rhamnose inducible vector construct which was provided by the Institute of Industrial Genetics, Universität Stuttgart (Germany). The restriction map is set forth in FIG. 1.

The hydantoinase was subjected to random mutagenesis using error-prone PCR. Approximately 10,000 clones were screened using a pH-indicator assay as described below:

1. *Seed culture plates:* plates containing 100  $\mu$ l/well LBamp were inoculated with single colonies/well and incubated for 24 hours at 30°C, 250 rpm.
2. *Main culture plates:* cells from seed culture plates were transferred with a 96-pin replicator into plates containing 200  $\mu$ l LBamp + 0.2% rhamnose. Plates were incubated for 24 hours at 30°C, 250 rpm.

3. Assay: using a pipetting robot, the culture of each well was mixed by pipetting up and down (3x) and transferred (75µl each) into two fresh plates. The two plates are filled with 100 µl/well freshly prepared substrate solution (80 mM D-MTEH and L-MTEH respectively, in 0.05 g/l cresol red pH 8.6). The absorbance at 580 nm is measured immediately after the substrate was added to the plate and after 3 hours incubation at room temperature. The activity was calculated as follows:

$$\text{Activity} = (A580(0h) - A580(3h)) / ((A580(0h) - 0.8)) \quad (\text{Rem: } 0.8 \text{ is the absorbance without cells})$$

For screening purposes, the ratio of activities for the D- and L-enantiomers is taken as an indicator for changed enantioselectivity.

Since the ratio of activities for different enantiomers in the screening tests is only a first hint of enantioselectivity, the identified mutants were confirmed by chiral HPLC using the racemic substrate as follows. 2ml overnight cultures were added to 2ml 80 mM DL-MTEH in 0.1M Tris pH8.5 and incubated at 37°C. After 1h and 2h respectively, the reaction mixture was centrifuged for 2 minutes, 14000 rpm. 20 µl of the supernatant was applied onto the HPLC column and the various fractions eluted.

About 2% of the population showed a significantly higher (>50%) activity compared to wild-type DSM 9771. Although a considerable number of those clones might be false positives due to common variation of expression level in a population, about 50% of rescreened clones were indeed higher activity mutants. The high number indicates that hydantoinase has a large evolutionary potential (its activity and enantioselectivity can be therefor improved). This can be rationalized since a high  $K_m$  value (about 15mM), a rather low specific activity (about 12U/mg) and a low expression level (<10% of total protein) leaves room for improvements of this enzyme.

Table 3 shows the results of the tested mutants. Mutant 1CG7 shows a dramatic increase of (D-) selectivity. Compared to wild-type, the enantiomeric excess of the product is 4 times increased. The enantioselectivity of clone 11DH7 and 19AG11 was changed into the opposite direction since both mutants are absolutely non-selective. The activity mutant 1BF7 possesses the same enantioselectivity as wild-type.

**TABLE 3**

Clone	Conversion	enantiomeric excess[%]
wild-type	42% after 2 hours	19
1CG7	42% after 2 hours	90
11DH7	42% after 2 hours	0
19AG11	37% after 2 hours	0
1BF7	45% after 1 hour	19

All of the mutants were sequenced and the nucleotide and amino acid sequences established as set forth in Table 4.

5

**TABLE 4**

	Nucleotide Sequence (SEQ. ID. NO.)	Amino Acid Sequence (SEQ. ID. NO.)
1CG7	3	4
11DH7	5	6
1BF7	7	8
19AG11	11	12

10 A second round of random mutagenesis was conducted using the first generation mutant 11DH7 as the parent.

Two different libraries with different error rates (20% and 50% inactive clones) were produced and 10,000 clones of each library were screened using the above-described pH-indicator method. None of the screened clones showed significantly higher L-selectivity but mutants with improved activity and higher D-selectivity were found. One mutant (22CG2) differing in only one amino acid (V180A) from the parent was found to be 4-fold more active compared to parent 11DH7.

15 Sequencing of the first generation mutants 11DH7 and 19AG11 revealed a single mutation (I95L) is responsible for their decreased D-selectivity. Introducing all 20 different amino acids into amino acid position 95 of mutant 22CG2 by saturation mutagenesis and screening of about 400 clones revealed a new mutant (Q2H4) with significantly improved L-selectivity (ee<sub>L</sub>=20%) and 1.5-fold improved activity compared to its parent 22CG2. The results of HPLC analysis for enantioselectivity are shown in FIG. 2. The

20

nucleotide and amino acid sequences for 22CG2 are set forth in SEQ. ID. NOS. 11 and 12, respectively. The nucleotide and amino acid sequences for Q2H4 are set forth in SEQ. ID. NOS. 13 and 14, respectively.

In addition to the improvements provided by the mutants described above, the activity of the whole cell catalyst could be increased by a factor of 10 by addition of 1 mM manganese to the growth medium and to the substrate solution. Under those conditions the activity of mutant 22CG2 was determined to be about 380 U/gCDW which is a 50-fold increase in activity compared to the activity described for *Arthrobacter* sp. DSM 9771. A comparison of the activity of mutant Q2H4 with other strains is given in FIG. 4.

A summary of the enzymatic activities of the various modified enzymes with respect to the parent DSM 9771 is set forth in FIG. 3. As can be seen from FIG. 3, all of the modified enzymes identified in accordance with the present invention have activities and/or enantioselectivity which are better than the unmodified DSM 9771 hydantoinase. When tested under standard conditions by HPLC, the Q2H4 mutant showed inverted enantioselectivity for the hydrolysis of D,L-MTEH. Q2H4 produced N-carbamoyl-L-methionine with an enantiomeric excess (ee) of 20% at about 30% conversion. In addition, the Q2H4 mutant was approximately 1.5-fold more active than its parent 22CG2.

### Example 2

In a further example, L-methionine was produced with a recombinant whole cell catalyst. Recombinant whole cell catalysts were prepared by co-expressing the evolved or wild-type hydantoinase with a hydantoin racemase and a L-carbamoylase in *E.coli* as follows.

**Strains and expression vectors.** The L-carbamoylase and hydantoinase expression vector pOM17 and pOM18 were constructed by PCR amplification of the *hyuC* and *hyuH* gene, respectively, from *Arthrobacter* sp. DSM 9771 using the following primer: for *hyuC*-amplification: 5'-AGGCGACATA-TGACCCTGCAGAAAGCGCAA-3' (SEQ. ID. NO. 17), 5'-ATGGGATCCCCGGT-CAAGTGCCTTCATTAC-3' (SEQ. ID. NO. 18); for *hyuH*-amplification: 5'-AGAACATATGTTTGACGTAATAGTTAAGAA-3' (SEQ. ID. NO. 15), 5'-AAAAGGAT-CCTCACTTCGACGCCTCGTA-3' (SEQ. ID. NO. 16). The amplified fragments were cleaved with the restriction enzymes NdeI and BamHI and inserted using the same restriction enzymes downstream the *rha* BAD promoter (rhamnose

promotor) into the vector pJOE2702 (Volff, J.-N., Eichenseer, C., Viell, P., Piendl, W. & Altenbuchner, J. (1996) Nucleotide sequence and role in DNA amplification of the direct repeats composing the amplifiable element AUDI of *Streptomyces lividans* 66. *Mol. Microbiol.* **21**, 1037-1047). The co-expression plasmid pOM20 comprising the L-carbamoylase and hydantoinase gene, both separately under the control of a rhamnose promotor, was derived from Plasmid pOM17 and pOM18. pOM17 was digested by Sall and treated with the Klenow fragment to form blunt ends. pOM18 was digested by BamHI and also treated with the Klenow fragment to form blunt ends. Both fragments were subsequently digested from HindII. The 1521 kb-fragment comprising the carbamoylase gene and rhamnose promotor derived from pOM17 was ligated with the 5650kb-fragment of the digested pOM18 to yield pOM20. Mutations of the L-selective hydantoinase were introduced into pOM20 using the restriction enzymes RsrII and KasI which yielded pOM22. The racemase expression vector pOM21 was derived from pACYC184 (Rose, R.E. The nucleotide sequence of pACYC184. *Nucleic Acids Res.* **16**, 355 (1988)) and carries a chloramphenicol selection marker and the racemase gene *hyuR* from *Arthrobacter sp.* DSM3747 under the control of the rhamnose promotor. All plasmids were routinely transformed into *E.coli* JM109 (Yanisch-Perron, C., Viera, J. & Messing, J. (1984) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13 mp18 and pUC vectors. *Gene* **33**, 103-109). The hydantoin converting pathway was installed in *E.coli* JM109 by transformation of pOM20 and pOM22, respectively into *E.coli* JM109 (pOM21). Cells were either grown in LB liquid medium or on LB-agar plates (Luria. S.E., Adams, J.N. & Ting, R.C. (1960) Transduction of lactose-utilizing ability among strains of *Escherichia coli* and *Shigella dysenteriae* and properties of phage particles. *Virology* **12**, 348-390), both supplemented with the respective antibiotics for the growth and expression medium (100 µg/ml ampicillin, 50 µg/ml chloramphenicol) and addition of 2 mg/ml rhamnose for the expression medium.

**Error-prone PCR.** Random mutagenesis of the hydantoinase gene was performed in a 100 µl reaction mix containing 0.25 ng of plasmid DNA as template, Boehringer PCR buffer (10 mM Tris, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, pH 8.3), 200 µM dATP, 200 µM dTTP, 200 µM dGTP, 200 µM dCTP, 50 pmol of each primer, and 2.5U *Taq* polymerase (Boehringer). After 30 cycles, the 1667 amplification product was extracted from gel using the QiaexII gel-extraction



kit (Qiagen, Valencia, CA) and subcloned into vector pJOE2702 using the *EcoRI* and *HindIII* restriction sites. Religation frequency of alkaline phosphatase treated vector was below 1%.

5       **Saturation mutagenesis.** For randomization of the codon for amino acid position 95, the QuickChange™ protocol (Stratagene, La Jolla, CA) was used. About 10 ng plasmid from clone 22CG2 were amplified by PCR using two complimentary oligonucleotides (5'-CATCGAGATGCCGNNNACCTTCCCG-CCCAC-3', 5-GTGGGCGGGAAGGTNNNCGGCATCTCGATG-3'). After PCR  
10       amplification the reaction mixture was treated for 2 hours with 20 U of the restriction enzyme DpnI. Transformation of 10 µl DpnI digested reaction mixture into competent cells yielded a library of more than 2000 mutants of which about 400 were screened.

15       **Preparation of library and screening.** Single colonies of transformed *E.coli* were transferred into 384-well plates (master plates) using the robot system Qbot (Genetix, Dorset, UK). After 20 hour growth at 37°C plates were stored at -80°C. For subsequent screening, plates were thawed and replicated into 96-well plates containing 200 µl per well inductor medium. A Biomek 1000  
20       pipetting workstation (Beckman, Fullerton, CA) was used to divide the 24 hours at 30°C incubated plate into two fresh 96-well plates one containing 100 µl 80 mM L-MTEH the other 100 µl 80mM D-MTEH in 50 mg/l cresol red solution adjusted to pH 8.5. Initial absorbance at 580 nm and after 3 hours incubation at room temperature were measured using a THERMOmax plate  
25       reader (Molecular Devices, Sunnyvale, CA). Activity was calculated from the difference of initial and absorbance after 3 hours incubation divided by the cell density of each well. For the saturation mutagenesis library incubation time was reduced to 1.5 hours. The ratio of activity towards the L- and D-enantiomer was taken as a first indicator for enantioselectivity. Identified  
30       clones were then tested using the racemic substrate under conditions described below.

35       **Characterization of activity and enantioselectivity.** Plasmid of mutant found to be positive in the screen was sequenced and retransformed into *E.coli*. A culture of retransformed *E.coli* was grown for 16-18 hours (until OD10) in inductor medium supplemented with 1mM MnCl<sub>2</sub>. 2 ml substrate solution

consisting of 80 mM D,L-MTEH, 0.1M Tris pH 8.5, 1 mM MnCl<sub>2</sub> (pre-incubated at 37°C) were added to 2 ml cell culture (OD<sub>600</sub>~7). The reaction mixture was immediately incubated at 37°C in a water bath. After different time periods (as specified in the text) 1 ml samples were taken and centrifuged for 5 minutes at 14,000 rpm. 20 µl of supernatant were analyzed by chiral HPLC using a column manufactured by Degussa-Huels AG. Activity was calculated from the amount of produced N-carbamoyl-D,L-methionine and expressed as U/ml cell culture of U/mg cell dry weight (CDW) where 1U is the amount of whole-cell catalyst to produce 1 µmol N-carbamoyl-D,L-methionine in one minute under stated reaction conditions. Enantioselectivity of the hydantoinase and its mutants were compared by calculating the percentage of ee<sub>D</sub> ((D-L)/(D+L)) and ee<sub>L</sub> ((L-D)/(L+D)) respectively for the product at various extents of conversion. A conventional determination of E (enantiomeric ratio) from ee-values and the extent of conversion as described by Chen et al. (Chen, C.S., Fujimoto, Y., Girdaukas, G. & Sih, C.J. (1982) Quantitative analysis of biochemical kinetic resolutions of enantiomers. *J. Am. Chem. Soc.* **104**, 7294-7299) is not possible because of the fast racemization of the substrate.

**Conversion of D,L-MTEH into L-met.** 8 mg cell dry mass of *E.coli* JM109 (pOM20 & pOM21) and *E.coli* JM109 (pOM 22 & pOM21) were added to 4 ml 100 mM D,L-MTEH in 0.1 M Tris pH 7.8 supplemented with 1mM MnCl<sub>2</sub>. The reaction mixture was incubated at 37°C. Samples were analyzed after indicated periods of time and analyzed by HPLC for MTEH, D,L-C met, and D,L-met as described in Völkel, D. & Wagner, F. Reaction (1995) mechanism for the conversion of 5-monosubstituted hydantoins to enantiomerically pure L-amino acids. *Ann. NY Acad. Sci.* **750**, 1-9. The optical purity of the compounds was analyzed by chiral HPLC as described above.

As shown in FIG. 5, the conversion of D,L-MTEH into L-met is significantly improved for the catalyst with the evolved hydantoinase. After three hours, approximately 60 mM L-met was produced from 100 mM D,L-MTEH, whereas the whole cell catalyst with the wild-type pathway produced only 10 mM of the amino acid. The concentration of the D-C met intermediate was reduced by a factor of 4 and the productivity for the production of L-amino acid was 8-fold increased during the first hour of the reaction.

### Example 3

The following example shows that production of L-methionine was significantly improved with an evolved hydantoinase of mutant 22CG2 which has improved activity and is not enantioselective (0% enantiomeric excess at 42% conversion, see Table 3). Mutations of the evolved hydantoinase from mutant 22CG2 were introduced into pOM20 as previously described using the restriction enzymes RsrII and KasI, which yielded pOM23. This co-expression vector was transformed into *E.coli* JM109 (pOM21). The resulting whole cell catalyst *E.coli* JM109 (pOM21/pOM23) and *E.coli* JM109 (pOM21/pOM20) were used for conversion of D,L-MTEH into methionine. 125 mg cell dry mass of the respective cells were added to 5 ml substrate solution (100 mM D,L-MTEH in 0.9% NaCl, 1mM MnCl<sub>2</sub>, pH 7.8) and incubated for 1 hour at 37°C. FIG. 6 shows the production of methionine (Met) and N-carbamoyl-methionine (C-Met) from D,L-MTEH for both catalysts. The whole cell catalyst with the improved hydantoinase from clone 22CG2 produced about 65 mM methionine within one hour whereas whole cell catalyst with the wild-type hydantoinase produced only 8 mM during the same reaction time. This demonstrates that an evolved hydantoinase without significant enantioselectivity but improved activity leads to a significant improvement for the production of methionine.

Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.

BIBLIOGRAPHY

1. Stinson, S.C. Counting on chiral drugs. *Chem. Eng. News* 76, 83-104.
2. Syltatk, C., Müller, R., Siemann, M. and Wagner, F. Microbial and enzymatic production of D-amino acids from DL-5-monosubstituted hydantoins. Hydrolysis and formation of hydantoins in Biocatalytic Production of Amino Acids and Derivatives (eds. Rozzell, J.D. and Wagner, F.) 75-127 (Hanser Publisher, New York, 1992).
3. Syltatk, C., Müller, R., Pietzsch, M. and Wagner, F. Microbial and enzymatic production of L-amino acids from DL-5-monosubstituted hydantoins. Hydrolysis and formation of hydantoins in Biocatalytic Production of Amino Acids and Derivatives (eds. Rozzell, J.D. and Wagner, F.) 131-1176 (Hanser Publisher, New York, 1992).
4. Drauz, K. (1997) Chiral amino acids: a versatile tool in the synthesis of pharmaceuticals and fine chemicals. *Chimia* 51, 310-314.
5. Wagner, F., Hantke, B., Wagner, T., Drauz & K., Bommarius, A. (1998) Microorganism, use thereof and process for production of L-alpha.-amino acids. US patent 5714355.
6. May, O., Siemann, M., Pietzsch, M., Kiess, M., Mattes, R. & Syltatk, C. (1998) Substrate-dependent enantioselectivity of a novel hydantoinase from *Arthrobacter aurescens* DSM 3745: purification and characterization as a new member of cyclic amidases. *J. Biotechnol.* 61, 1-13.
7. Wagner, T., Hantke, B. & Wagner, F. (1996) Production of L-methionine from D,L-5-(2-methylthioethyl)hydantoin by resting cells of a mutant strain of *Arthrobacter species* DSM 7330. *J. Biotechnol.* 46, 63-69.
8. Völkel, D. & Wagner, F. (1995) Reaction mechanism for the conversion of 5-monosubstituted hydantoins to enantiomerically pure L-amino acids. *Ann. NY Acad. Sci.* 750, 1-9.
9. Arnold, F.H. and Moore, J.C. (1997) Optimizing industrial enzymes by directed evolution. *Adv. Biochem. Eng. Biotech.* 58, 1-14.
10. Arnold, F.H. & Wintrode, P.L. Enzymes, directed evolution in Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis, and Bioseparation. (eds. Flickinger, M.C. & Drew, S.W.) 971-987 (John Wiley & Sons, Inc., New York, 1999).
11. Matcham, G.W. & Bowen, A.R.S. (1996) Biocatalysis for chiral intermediates: Meeting commercial and technical challenges. *CHIM. OGGI* 14, 20-24.
12. Reetz, M.T., Zonta, A., Schimossek, K., Liebeton, K. & Jaeger, K.-E. (1998) Creation of enantioselective biocatalysts for organic chemistry by in vitro evolution. *Angew. Chem. Int Ed.* 36, 2830-2832.
13. Reetz, M.T. & Jaeger, K.-E. (1999) Superior biocatalysts by directed evolution. *Top. Curr. Chem.* 200, 31-57.

14. Miyazaki, K. and Arnold, F.H. Exploring Nonnatural Evolutionary Pathways by Saturation Mutagenesis: Rapid Improvement of Protein Function. *J. Molecular Evolution*, in press.
15. Handelsman, J., Rondon, M.R., Brady, S.F., Clardy, J. & Goodman, R.M. (1998) Molecular biological access to the chemistry of unknown soil microbes: A new frontier for natural products. *Chem. Biol.* 5, R245-R249.
16. Fersht, A. (ed.) in *Enzyme structure and mechanism*. p. 350 (W.H. Freeman and Company, New York, 1985).
17. Bailey, J.E. (1999) Lessons from metabolic engineering for functional genomics and drug discovery. *Nat. Biotechnol.* 17, 616-618.
18. Volff, J.-N., Eichenseer, C., Viell, P., Piendl, W. & Altenbuchner, J. (1996) Nucleotide sequence and role in DNA amplification of the direct repeats composing the amplifiable element AUDI of *Streptomyces lividans*. 66 *Mol. Microbiol.* 21, 1037-1047.
19. Rose, R.E. (1988) The nucleotide sequence of pACYC184. *Nucleic Acids Res.* 16, 355.
20. Yanisch-Perron, C., Viera, J. & Messing, J. (1984) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13 mp18 and pUC vectors. *Gene* 33, 103-109.
21. Luria, S.E., Adams, J.N. & Ting, R.C. (1960) Transduction of lactose-utilizing ability among strains of *Escherichia coli* and *Shigella dysenteriae* and properties of phage particles. *Virology* 12, 348-390.
22. Chen, C.S., Fujimoto, Y., Girdaukas, G. & Sih, C.J. (1982) Quantitative analysis of biochemical kinetic resolutions of enantiomers. *J. Am. Chem. Soc.* 104, 7294-7299.

CLAIMSWhat is claimed is:

1. A modified hydantoinase having improved enzymatic properties relative to unmodified hydantoinase of SEQ. ID. NO: 1, wherein said modified hydantoinase consists of unmodified hydantoinase which has been modified by an amino acid substitution at one or more amino acid positions selected from the group consisting of amino acid position numbers 95, 154, 180, 251 and 255 and equivalent positions of other hydantoinases.
2. A modified hydantoinase according to claim 1 wherein said one or more amino acid substitutions are selected from the group consisting of I95F, I95L, V154A, V180A, Q251R and V255A.
3. A modified hydantoinase according to claim 1 wherein said unmodified hydantoinase is modified by the amino acid substitutions I95F, V180A and Q251R.
4. A modified hydantoinase according to claim 1 wherein said unmodified hydantoinase is modified by the amino acid substitutions V180A and Q251R.
5. A modified hydantoinase according to claim 1 wherein said unmodified hydantoinase is modified by the amino acid substitutions I95L and Q251R.
6. A modified hydantoinase according to claim 1 wherein said unmodified hydantoinase is modified by the amino acid substitution V154A.
7. A modified hydantoinase according to claim 1 wherein said unmodified hydantoinase is modified by the amino acid substitution V255A.
9. A modified hydantoinase according to claim 1 wherein said unmodified hydantoinase is modified by the amino acid substitution I95L.
10. A nucleic acid segment comprising a region which encodes a modified hydantoinase having improved enzymatic properties relative to

unmodified hydantoinase of SEQ. ID. NO. 1, wherein said modified  
hydantoinase consists of unmodified hydantoinase which has been modified by  
an amino acid substitution at one or more amino acid positions selected from  
the group consisting of amino acid position numbers 95, 154, 180, 251 and  
255 and equivalent positions of other hydantoinases.

11. A nucleic acid segment according to claim 10 wherein said one  
or more amino acid substitutions are selected from the group consisting of  
I95F, I95L, V154A, V180A, Q251R and V255A.

12. An expression vector containing a nucleic acid segment  
according to claim 10.

13. An expression vector containing a nucleic acid segment  
according to claim 11.

14. A host cell comprising a nucleic acid segment according to  
claim 10.

15. A host cell comprising a nucleic acid segment according to  
claim 11.

16. A method for producing a modified hydantoinase wherein said  
method comprises the steps of:

expressing a nucleic acid segment encoding said modified  
hydantoinase according to claim 10 in a suitable host cell to produce modified  
hydantoinase; and

recovering said modified hydantoinase produced by said  
expression step.

17. A method for producing a modified hydantoinase wherein said  
method comprises the steps of:

expressing a nucleic acid segment encoding said modified  
hydantoinase according to claim 11 in a suitable host cell to produce modified  
hydantoinase; and

recovering said modified hydantoinase produced by said  
expression step.

18. Process for the production of amino acids utilizing a modified hydantoinase according to claim 1.
19. Process according to claim 18 characterized in that a modified hydantoinase according to claim 2 is utilized.
20. Process according to claim 18 characterized in that accompanied with the hydantoinase a carbamoylase and a hydantoin racemase is used.
21. Process according to claim 18 characterized in that free or immobilized hydantoinase is used.
22. Process according to claim 18 characterized in that alanine, leucine, isoleucine, methionine, valine or tert.-leucine or neopentyl glycine are produced.
23. Process according to claim 18 characterized in that the process is performed in an enzyme-membrane-reactor.
24. Whole cell catalyst comprising a gene encoding for a hydantoinase wherein the hydantoinase is considered to be according to claim 1.
25. A whole cell catalyst according to claim 24 which further comprises a gene encoding for a carbamoylase.
26. A whole cell catalyst according to claim 25 which further comprises a gene encoding for a racemase.
27. A whole cell catalyst according to claim 24 characterized in that a bacteria is used as a whole cell.
28. A whole cell catalyst according to claims 24 characterized in that Escherichia coli is used as a whole cell.



29. Process for the production of amino acids utilizing whole cell catalysts according to claim **24**.

30. Process according to claim **27** characterized in that methionine, valine, threonine, lysine or tert.-leucine is produced.

31. Process according to claims **27** characterized in that the process is performed in an enzyme-membrane-reactor.

32. Process for the production of a whole cell catalyst according to claim **24**, wherein expression vectors pOM17, pOM18, pOM20, pOM22 and/or pOM21 are used.

33. Process according to claim **32** wherein primers of SEQ. NO. 17, SEQ. NO. 18, SEQ. NO. 15 and/or SEQ. NO. 16 are used.

34. A process for production of alpha-amino acids using a whole cell catalyst containing an improved hydantoinase of claim **1** where the N-carbamoyl-D-amino acid or N-carbamoyl-L-amino acid that is produced by the action of the hydantoinase is further chemically or enzymatically hydrolyzed to produce the amino acid and where the racemization of the hydantoin is achieved either chemically or enzymatically.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANTS: Arnold, Frances H.; May Oliver; Drauz, Karlheinz;  
Bommarius, Andreas
- (ii) TITLE OF INVENTION: Hydantoinase Variants With Improved  
Properties And Their Use For The  
Production Of Amino Acids
- (iii) NUMBER OF SEQUENCES: 18
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Oppenheimer Wolff & Donnelly LLP
  - (B) STREET: 2029 Century Park East, Suite 3800
  - (C) CITY: Los Angeles
  - (D) STATE: California
  - (E) COUNTRY: USA
  - (F) ZIP: 90067
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy Disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: Microsoft Windows 98
  - (D) SOFTWARE: MS Word
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 60/126,923
  - (B) FILING DATE: March 29, 1999
  - (A) APPLICATION NUMBER: 60/157,427
  - (B) FILING DATE: October 4, 1999
  - (A) APPLICATION NUMBER: 09/497,585
  - (B) FILING DATE: February 3, 2000
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Oldenkamp, David J.
  - (B) REGISTRATION NUMBER: 29,421
  - (C) REFERENCE/DOCKET NUMBER: 330187-93
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (310) 788-5000
  - (B) TELEFAX: (310) 277-1297

## (2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1377 nucleotides
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 1

```

atgtttgacg taatagttaa gaactgccgt atggtgtcca gcgacggaat caccgaggca      60
gacattcttg tgaaagacgg caaagtcgcc gcaatcagct cggacacaag tgatgttgag      120
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggg cgatgaacat      180
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggg cgatgaacat      240
tctgcggccg tgggaggcat caccaccatc atcgagatgc cgataacctt cccgccacc      300
accacttttg acgccttcct cgaaaagaag aagcaggcgg ggcagcgggt gaaagttgac      360
ttcgcgctct atggcgggtg agtgccggga aacctgccc agatccgcaa aatgcacgac      420
gccggcgacg tgggcttcaa gtcaatgatg gcagcctcag ttccgggcat gttcgacgcc      480
gtcagcgacg gcgaactgtt cgaaatcttc caggagatcg cagcctgtgg ttcagtcgtc      540
gtggtccatg ccgagaatga aacgatcatt caagcgctcc agaagcagat caaagccgct      600
ggtcgcaagg acatggccgc ctacgaggca tccaaccag tttccagga gaacgaggcc      660
attcagcgtg cgttactact gcagaaaagaa gccggctgtc gactgattgt gcttcacgtg      720
agcaacctg acggggtcga gctgatacat caggcgcaat ccgaggcca ggacgtccac      780
tgcgagtcgg gtccgcagta tctgaatac accacggacg acgccgaacg aatcgaccg      840
tatatgaagg tcgcgccgcc cgtccgctca gccgagatga acgtcagatt atgggaacaa      900
cttgagaacg ggctcatcga cacccttggg tcagaccacg gccgacatcc tgtcgaggac      960
aaagaacccg gctggaagga cgtgtggaaa gccggcaacg gtgcgctggg ccttgagaca     1020
tccctgccta tgatgctgac caacggagtg aataaaggca ggctatcctt ggaacgcctc     1080
gtcgaggtga tgtcgagaaa acctgcgaag ctctttggca tctatccgca gaagggcacg     1140
ctacaggttg gttccgacgc cgatctgctc atcctcgatc tggatattga caccaaagtg     1200
gatgcctcgc agttccgatc cctgcataag tacagcccgt tcgacgggat gcccgtcacg     1260
ggtgcaccgg ttctgacgat ggtgcgcgga acggtgggtg cagagaaggg agaagttctg     1320
gtcgagcagg gattcgcca gttcgtcacc cgtcacgact acgaggcgtc gaagtga      1377

```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 2

```

Met Phe Asp Val Ile Val Lys Asn Cys Arg Met Val Ser Ser Asp Gly
      5              10              15
Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile
      20              25              30
Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly
      35              40              45
Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile
      50              55              60
Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu
      65              70              75              80

```

Ser	Ala	Ala	Val	Gly	Gly	Ile	Thr	Thr	Ile	Ile	Glu	Met	Pro	Ile	Thr	85	90	95
Phe	Pro	Pro	Thr	Thr	Thr	Leu	Asp	Ala	Phe	Leu	Glu	Lys	Lys	Lys	Gln	100	105	110
Ala	Gly	Gln	Arg	Leu	Lys	Val	Asp	Phe	Ala	Leu	Tyr	Gly	Gly	Gly	Val	115	120	125
Pro	Gly	Asn	Leu	Pro	Glu	Ile	Arg	Lys	Met	His	Asp	Ala	Gly	Ala	Val	130	135	140
Gly	Phe	Lys	Ser	Met	Met	Ala	Ala	Ser	Val	Pro	Gly	Met	Phe	Asp	Ala	145	150	160
Val	Ser	Asp	Gly	Glu	Leu	Phe	Glu	Ile	Phe	Gln	Glu	Ile	Ala	Ala	Cys	165	170	175
Gly	Ser	Val	Val	Val	Val	His	Ala	Glu	Asn	Glu	Thr	Ile	Ile	Gln	Ala	180	185	190
Leu	Gln	Lys	Gln	Ile	Lys	Ala	Ala	Gly	Arg	Lys	Asp	Met	Ala	Ala	Tyr	195	200	205
Glu	Ala	Ser	Gln	Pro	Val	Phe	Gln	Glu	Asn	Glu	Ala	Ile	Gln	Arg	Ala	210	215	220
Leu	Leu	Leu	Gln	Lys	Glu	Ala	Gly	Cys	Arg	Leu	Ile	Val	Leu	His	Val	225	230	235
Ser	Asn	Pro	Asp	Gly	Val	Glu	Leu	Ile	His	Gln	Ala	Gln	Ser	Glu	Gly	245	250	255
Gln	Asp	Val	His	Cys	Glu	Ser	Gly	Pro	Gln	Tyr	Leu	Asn	Ile	Thr	Thr	260	265	270
Asp	Asp	Ala	Glu	Arg	Ile	Gly	Pro	Tyr	Met	Lys	Val	Ala	Pro	Pro	Val	275	280	285
Arg	Ser	Ala	Glu	Met	Asn	Val	Arg	Leu	Trp	Glu	Gln	Leu	Glu	Asn	Gly	290	295	300
Leu	Ile	Asp	Thr	Leu	Gly	Ser	Asp	His	Gly	Gly	His	Pro	Val	Glu	Asp	305	310	315
Lys	Glu	Pro	Gly	Trp	Lys	Asp	Val	Trp	Lys	Ala	Gly	Asn	Gly	Ala	Leu	325	330	335
Gly	Leu	Glu	Thr	Ser	Leu	Pro	Met	Met	Leu	Thr	Asn	Gly	Val	Asn	Lys	340	345	350
Gly	Arg	Leu	Ser	Leu	Glu	Arg	Leu	Val	Glu	Val	Met	Cys	Glu	Lys	Pro	355	360	365
Ala	Lys	Leu	Phe	Glu	Ile	Tyr	Pro	Gln	Lys	Gly	Thr	Leu	Gln	Val	Gly	370	375	380

Ser Asp Ala Asp Leu Leu Ile Leu Asp Leu Asp Ile Asp Thr Lys Val  
 385 390 395 400

Asp Ala Ser Gln Phe Arg Ser Leu His Lys Tyr Ser Pro Phe Asp Gly  
 405 410 415

Met Pro Val Thr Gly Ala Pro Val Leu Thr Met Val Arg Gly Thr Val  
 420 425 430

Val Ala Glu Lys Gly Glu Val Leu Val Glu Gln Gly Phe Gly Gln Phe  
 435 440 445

Val Thr Arg His Asp Tyr Glu Ala Ser Lys  
 450 455 458

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1377 nucleotides  
 (B) TYPE: nucleotide  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: nucleic acid

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 3

atgtttgacg	taatagttaa	gaactgccgt	atgggtgtcca	gcgacggaat	caccgaggca	60
gacattcttg	tgaagacgg	caaagtgcgc	gcaatcagct	cggacacaag	tgatgttgag	120
gcgagccgaa	ccattgacgc	gggtggcaag	ttcgtgatgc	cgggcggtgt	cgatgaacat	180
gcgagccgaa	ccattgacgc	gggtggcaag	ttcgtgatgc	cgggcggtgt	cgatgaacat	240
tctgcggccg	tgggaggcat	caccaccatc	atcgagatgc	cgataacctt	cccgccacc	300
accacttttg	acgccttcct	cgaaaagaag	aagcaggcgg	ggcagcggtt	gaaagttgac	360
ttcgcgctct	atggcggttg	agtgccggga	aacctgcccg	agatccgcaa	aatgcacgac	420
gccggcgag	tgggcttcaa	gtcaatgatg	gcagcctcag	ctccgggcat	gttcgacgcc	480
gtcagcgacg	gcgaactgtt	cgaaatcttc	caggagatcg	cagcctgtgg	ttcagtcgtc	540
gtgttccatg	ccgagaatga	aacgatcatt	caagcgctcc	agaagcagat	caaagccgct	600
ggtcgcaagg	acatggccgc	ctacgaggca	tcccaaccag	ttttccagga	gaacgaggcc	660
attcagcggtg	cgttactact	gcagaaaaga	gccggctgtc	gactgattgt	gcttcacgtg	720
agcaaccctg	acggggtcga	gctgatacat	caggcgcaat	ccgagggccca	ggacgtccac	780
tgcgagtcgg	gtccgcagta	tctgaatatc	accacggacg	acgccgaacg	aatcggaaccg	840
tatatgaagg	tcgcgccgcc	cgtcgcgtca	gccgagatga	acgtcagatt	atgggaacaa	900
cttgagaacg	ggctcatcga	cacccttggg	tcagaccacg	gcggacatcc	tgtcgaggac	960
aaagaacccg	gctggaagga	cgtgtggaaa	gccggcaacg	gtgcgctggg	ccttgagaca	1020
tccctgccta	tgatgctgac	caacggagtg	aataaaggca	ggctatcctt	ggaacgcctc	1080
gtcagaggtga	tgtgcgagaa	acctgcgaag	ctctttggca	tctatccgca	gaagggcacg	1140
ctacagggtt	gttcggacgc	cgatctgttc	atcctcgatc	tgatatttga	caccaaagtg	1200
gatgcctcgc	agttccgatc	cctgcataag	tacagcccgt	tcgacgggat	gcccgtcacg	1260
ggtgcaccgg	ttctgacgat	ggtgcgcgga	acggtggttg	cagagaaggg	agaagttctg	1320
gtcgagcagg	gattcggccca	gttcgtcacc	cgtcacgact	acgaggcgtc	gaagtga	1377

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 4

```

Met Phe Asp Val Ile Val Lys Asn Cys Arg Met Val Ser Ser Asp Gly
      5              10              15

Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile
      20              25              30

Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly
      35              40              45

Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile
      50              55              60

Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu
      65              70              75              80

Ser Ala Ala Val Gly Gly Ile Thr Thr Ile Ile Glu Met Pro Ile Thr
      85              90              95

Phe Pro Pro Thr Thr Thr Leu Asp Ala Phe Leu Glu Lys Lys Lys Gln
      100             105             110

Ala Gly Gln Arg Leu Lys Val Asp Phe Ala Leu Tyr Gly Gly Gly Val
      115             120             125

Pro Gly Asn Leu Pro Glu Ile Arg Lys Met His Asp Ala Gly Ala Val
      130             135             140

Gly Phe Lys Ser Met Met Ala Ala Ser Ala Pro Gly Met Phe Asp Ala
      145             150             155             160

Val Ser Asp Gly Glu Leu Phe Glu Ile Phe Gln Glu Ile Ala Ala Cys
      165             170             175

Gly Ser Val Val Val Val His Ala Glu Asn Glu Thr Ile Ile Gln Ala
      180             185             190

Leu Gln Lys Gln Ile Lys Ala Ala Gly Arg Lys Asp Met Ala Ala Tyr
      195             200             205

Glu Ala Ser Gln Pro Val Phe Gln Glu Asn Glu Ala Ile Gln Arg Ala
      210             215             220

Leu Leu Leu Gln Lys Glu Ala Gly Cys Arg Leu Ile Val Leu His Val
      225             230             235             240

```

Ser	Asn	Pro	Asp	Gly	Val	Glu	Leu	Ile	His	Gln	Ala	Gln	Ser	Glu	Gly	245	250	255
Gln	Asp	Val	His	Cys	Glu	Ser	Gly	Pro	Gln	Tyr	Leu	Asn	Ile	Thr	Thr	260	265	270
Asp	Asp	Ala	Glu	Arg	Ile	Gly	Pro	Tyr	Met	Lys	Val	Ala	Pro	Pro	Val	275	280	285
Arg	Ser	Ala	Glu	Met	Asn	Val	Arg	Leu	Trp	Glu	Gln	Leu	Glu	Asn	Gly	290	295	300
Leu	Ile	Asp	Thr	Leu	Gly	Ser	Asp	His	Gly	Gly	His	Pro	Val	Glu	Asp	305	310	315
Lys	Glu	Pro	Gly	Trp	Lys	Asp	Val	Trp	Lys	Ala	Gly	Asn	Gly	Ala	Leu	325	330	335
Gly	Leu	Glu	Thr	Ser	Leu	Pro	Met	Met	Leu	Thr	Asn	Gly	Val	Asn	Lys	340	345	350
Gly	Arg	Leu	Ser	Leu	Glu	Arg	Leu	Val	Glu	Val	Met	Cys	Glu	Lys	Pro	355	360	365
Ala	Lys	Leu	Phe	Glu	Ile	Tyr	Pro	Gln	Lys	Gly	Thr	Leu	Gln	Val	Gly	370	375	380
Ser	Asp	Ala	Asp	Leu	Leu	Ile	Leu	Asp	Leu	Asp	Ile	Asp	Thr	Lys	Val	385	390	395
Asp	Ala	Ser	Gln	Phe	Arg	Ser	Leu	His	Lys	Tyr	Ser	Pro	Phe	Asp	Gly	405	410	415
Met	Pro	Val	Thr	Gly	Ala	Pro	Val	Leu	Thr	Met	Val	Arg	Gly	Thr	Val	420	425	430
Val	Ala	Glu	Lys	Gly	Glu	Val	Leu	Val	Glu	Gln	Gly	Phe	Gly	Gln	Phe	435	440	445
Val	Thr	Arg	His	Asp	Tyr	Glu	Ala	Ser	Lys							450	455	458

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1377 nucleotides  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: nucleic acid

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 5

atgtttgacg taatagttaa gaactgccgt atggtgtcca gcgacggaat caccgaggca	60
gacattcttg tgaaagacgg caaagtcgcc gcaatcagct cggacacaag tgatgttgag	120
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat	180
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat	240
tctgcggccg tgggaggcat caccaccatc atcgagatgc cgttaacctt cccgcccacc	300
accactttgg acgccttcct cgaaaagaag aagcaggcgg ggacgcggtt gaaagttgac	360
ttcgcgctct atggcggtag agtgccggga aacctgccg agatccgcaa aatgcacgac	420
gccggcgtag tgggcttcaa gtcaatgatg gcagcctcag ttccgggcat gttcgacgcc	480
gtcagcgacg gcgaactggt cgaaatcttc caggagatcg cagcctgtgg ttcagtcgtc	540
gtggtccatg ccgagaatga aacgatcatt caagcgctcc agaagcagat caaagccgct	600
ggtcgcaagg acatggccgc ctacgaggca tccaaccag tttccagga gaacgaggcc	660
attcagcgtg cgttactact gcagaaagaa gccggctgtc gactgattgt gcttcacgtg	720
agcaaccctg acggggtcga gctgatacat caggcgcaat ccgagggcca ggacgtccac	780
tgcgagtcgg gtccgcagta tctgaatatc accacggacg acgccgaacg aatcggaccg	840
tatatgaagg tcgcgccgcc cgtccgctca gccgagatga acgtcagatt atgggaacaa	900
cttgagaacg ggctcatcga cacccttggt tcagaccacg gcggacatcc tgtcgaggac	960
aaagaacccg gctggaagga cgtgtggaaa gccggcaacg gtgcgctggg ccttgagaca	1020
tcctgccta tgatgctgac caacggagtg aataaaggca ggctatcctt ggaacgcctc	1080
gtcgaggtga tgtgcgagaa acctgcgaag ctctttggca tctatccgca gaagggcacg	1140
ctacaggttg gttccgacgc cgatctgctc atcctcgatc tggatattga caccaaagtg	1200
gatgcctcgc agttccgatc cctgcataag tacagcccgt tcgacgggat gcccgtcacg	1260
ggtgcaccgg ttctgacgat ggtgcgcgga acggtggtgg cagagaaggg agaagttctg	1320
gtcgagcagg gattcggcca gttcgtcacc cgtcacgact acgaggcgtc gaagtga	1377

## (2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 458 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear



(ii) MOLECULE TYPE: protein

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 6

```

Met Phe Asp Val Ile Val Lys Asn Cys Arg Met Val Ser Ser Asp Gly
      5              10              15

Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile
      20              25              30

Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly
      35              40              45

Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile
      50              55              60

Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu
      65              70              75              80

Ser Ala Ala Val Gly Gly Ile Thr Thr Ile Ile Glu Met Pro Leu Thr
      85              90              95

Phe Pro Pro Thr Thr Thr Leu Asp Ala Phe Leu Glu Lys Lys Lys Gln
      100             105             110

Ala Gly Gln Arg Leu Lys Val Asp Phe Ala Leu Tyr Gly Gly Gly Val
      115             120             125

Pro Gly Asn Leu Pro Glu Ile Arg Lys Met His Asp Ala Gly Ala Val
      130             135             140

Gly Phe Lys Ser Met Met Ala Ala Ser Val Pro Gly Met Phe Asp Ala
      145             150             155             160

Val Ser Asp Gly Glu Leu Phe Glu Ile Phe Gln Glu Ile Ala Ala Cys
      165             170             175

Gly Ser Val Val Val Val His Ala Glu Asn Glu Thr Ile Ile Gln Ala
      180             185             190

Leu Gln Lys Gln Ile Lys Ala Ala Gly Arg Lys Asp Met Ala Ala Tyr
      195             200             205

Glu Ala Ser Gln Pro Val Phe Gln Glu Asn Glu Ala Ile Gln Arg Ala
      210             215             220

Leu Leu Leu Gln Lys Glu Ala Gly Cys Arg Leu Ile Val Leu His Val
      225             230             235             240

Ser Asn Pro Asp Gly Val Glu Leu Ile His Arg Ala Gln Ser Glu Gly
      245             250             255

Gln Asp Val His Cys Glu Ser Gly Pro Gln Tyr Leu Asn Ile Thr Thr
      260             265             270

```

Asp Asp Ala Glu Arg Ile Gly Pro Tyr Met Lys Val Ala Pro Pro Val  
 275 280 285  
 Arg Ser Ala Glu Met Asn Val Arg Leu Trp Glu Gln Leu Glu Asn Gly  
 290 295 300  
 Leu Ile Asp Thr Leu Gly Ser Asp His Gly Gly His Pro Val Glu Asp  
 305 310 315 320  
 Lys Glu Pro Gly Trp Lys Asp Val Trp Lys Ala Gly Asn Gly Ala Leu  
 325 330 335  
 Gly Leu Glu Thr Ser Leu Pro Met Met Leu Thr Asn Gly Val Asn Lys  
 340 345 350  
 Gly Arg Leu Ser Leu Glu Arg Leu Val Glu Val Met Cys Glu Lys Pro  
 355 360 365  
 Ala Lys Leu Phe Glu Ile Tyr Pro Gln Lys Gly Thr Leu Gln Val Gly  
 370 375 380  
 Ser Asp Ala Asp Leu Leu Ile Leu Asp Leu Asp Ile Asp Thr Lys Val  
 385 390 395 400  
 Asp Ala Ser Gln Phe Arg Ser Leu His Lys Tyr Ser Pro Phe Asp Gly  
 405 410 415  
 Met Pro Val Thr Gly Ala Pro Val Leu Thr Met Val Arg Gly Thr Val  
 420 425 430  
 Val Ala Glu Lys Gly Glu Val Leu Val Glu Gln Gly Phe Gly Gln Phe  
 435 440 445  
 Val Thr Arg His Asp Tyr Glu Ala Ser Lys  
 450 455 458

## (2) INFORMATION FOR SEQ ID NO: 7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1377 nucleotides
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: nucleic acid

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 7

atgtttgacg taatagttaa gaactgccgt atggtgtcca gcgacggaat caccgaggca 60  
 gacattctgg tgaaagacgg caaagtcgcc gcaatcagct cggacacaag tgatgttgag 120  
 gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat 180  
 gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat 240

tctgcggccg tgggagggcat caccaccatc atcgagatgc cgataacctt cccgcccacc	300
accacttttg acgccttctt cgaaaagaag aagcaggcgg ggcagcgggtt gaaagttgac	360
ttcgcgctct atggcggttg agtgccggga aacctgccc agatccgcaa aatgcacgac	420
gccggcgagc tgggcttcaa gtcaatgatg gcagcctcag ttccgggcat gttcgacgcc	480
gtcagcgacg gcgaactgtt cgaaatcttc caggagatcg cagcctgtgg ttcagtcgtc	540
gtggtccatg ccgagaatga aacgatcatt caagcgctcc agaagcagat caaagccgct	600
ggtcgcaagg acatggccgc ctacgaggca tccaaccag ttttccagga gaacgaggcc	660
attcagcgtg cgttactact gcagaaagaa gccggctgtc gactgattgt gcttcacgtg	720
agcaaccctg acgggggtcga gctgatacat caggcgcaat ccgagggcca ggacgtccac	780
tgcgagtcgg gtccgcagta tctgaatatt accacggacg acgccgaacg aatcggaaccg	840
tatatgaagg tcgcgcccgc cgtccgctca gccgagatga acgccagatt atgggaacaa	900
cttgagaacg ggctcatcga cacccttggg tcagaccacg gcggacatcc tgtcgaggac	960
aaagaacccg gctggaagga cgtgtggaaa gccggcaacg gtgcgctggg ccttgagaca	1020
tccctgccta tgatgctgac caacggagtg aataaaggca ggctatcctt ggaacgcctc	1080
gtcgaggtga tgtgcgagaa acctgcgaag ctctttggca tctatccgca gaagggcacg	1140
ctacaggttg gttccgacgc cgatctgtc atcctcgatc tggatattga caccaaagtg	1200
gatgcctcgc agttccgatc cctgcataag tacagcccgt tcgacgggat gcccgtcacg	1260
ggtgcaccgg ttctgacgat ggtgcgcgga acggtggtgg cagagaaggg agaagttctg	1320
gtcgagcagg gattcggcca gttcgtcacc cgtcacgact acgaggcgtc gaagtga	1377

## (2) INFORMATION FOR SEQ ID NO: 8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 8

Met	Phe	Asp	Val	Ile	Val	Lys	Asn	Cys	Arg	Met	Val	Ser	Ser	Asp	Gly
				5					10						15

Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile  
 20 25 30  
 Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly  
 35 40 45  
 Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile  
 50 55 60  
 Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu  
 65 70 75 80  
 Ser Ala Ala Val Gly Gly Ile Thr Thr Ile Ile Glu Met Pro Ile Thr  
 85 90 95  
 Phe Pro Pro Thr Thr Thr Leu Asp Ala Phe Leu Glu Lys Lys Lys Gln  
 100 105 110  
 Ala Gly Gln Arg Leu Lys Val Asp Phe Ala Leu Tyr Gly Gly Gly Val  
 115 120 125  
 Pro Gly Asn Leu Pro Glu Ile Arg Lys Met His Asp Ala Gly Ala Val  
 130 135 140  
 Gly Phe Lys Ser Met Met Ala Ala Ser Val Pro Gly Met Phe Asp Ala  
 145 150 155 160  
 Val Ser Asp Gly Glu Leu Phe Glu Ile Phe Gln Glu Ile Ala Ala Cys  
 165 170 175  
 Gly Ser Val Val Val Val His Ala Glu Asn Glu Thr Ile Ile Gln Ala  
 180 185 190  
 Leu Gln Lys Gln Ile Lys Ala Ala Gly Arg Lys Asp Met Ala Ala Tyr  
 195 200 205  
 Glu Ala Ser Gln Pro Val Phe Gln Glu Asn Glu Ala Ile Gln Arg Ala  
 210 215 220  
 Leu Leu Leu Gln Lys Glu Ala Gly Cys Arg Leu Ile Val Leu His Val  
 225 230 235 240  
 Ser Asn Pro Asp Gly Val Glu Leu Ile His Gln Ala Gln Ser Glu Gly  
 245 250 255  
 Gln Asp Val His Cys Glu Ser Gly Pro Gln Tyr Leu Asn Ile Thr Thr  
 260 265 270  
 Asp Asp Ala Glu Arg Ile Gly Pro Tyr Met Lys Val Ala Pro Pro Val  
 275 280 285  
 Arg Ser Ala Glu Met Asn Ala Arg Leu Trp Glu Gln Leu Glu Asn Gly  
 290 295 300  
 Leu Ile Asp Thr Leu Gly Ser Asp His Gly Gly His Pro Val Glu Asp  
 305 310 315 320



```

gtcagcgacg gcgaactgtt cgaaatcttc caggagatcg cagcctgtgg ttcagtcgtc      540
gtggtccatg ccgagaatga aacgatcatt caagcgtcc agaagcagat caaagccgct      600
ggtcgcaagg acatggccgc ctacgaggca tccaaccag tttccagga gaacgaggcc      660
attcagcgtg cgttactact gcagaaagaa gccggctgtc gactgattgt gcttcacgtg      720
agcaaccctg acgggggtcga gctgatacat caggcgcaat ccgagggcca ggacgtccac      780
tgcgagtcgg gtccgcagta tctgaatatc accacggacg acgccgaacg aatcggaccg      840
tatatgaagg tcgcgccgcc cgtccgctca gccgaaatga acgtcagatt atgggaacaa      900
cttgagaacg ggctcatcga cacccttggg tcagaccacg gcggacatcc tgcgaggac      960
aaagaacccg gctggaagga cgtgtggaaa gccggcaacg gtgcgctggg ccttgagaca     1020
tcctgccta tgatgctgac caacggagtg aataaaggca ggctatcctt ggaacgcctc     1080
gtcgaggtga tgtgcgagaa acctgcgaag ctctttggca tctatccgca gaagggcacg     1140
ctacaggttg gttccgacgc cgatctgtc atcctcgatc tggatattga caccaaagtg     1200
gatgcctcgc agttccgatc cctgcataag tacagcccg tgcacgggat gcccgtcacg     1260
ggtgcaccgg ttctgacgat ggtgcgcgga acggtggtgg cagagaaggg agaagttctg     1320
gtcgagcagg gattcggccg gttcgtcacc cgtcacgact acgaggcgtc gaagtga       1377

```

## (2) INFORMATION FOR SEQ ID NO: 10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 10

```

Met Phe Asp Val Ile Val Lys Asn Cys Arg Met Val Ser Ser Asp Gly
      5              10              15
Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile
      20              25              30
Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly
      35              40              45
Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile
      50              55              60

```

Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu  
 65 70 75 80  
 Ser Ala Ala Val Gly Gly Ile Thr Thr Ile Ile Glu Met Pro Leu Thr  
 85 90 95  
 Phe Pro Pro Thr Thr Thr Leu Asp Ala Phe Leu Glu Lys Lys Lys Gln  
 100 105 110  
 Ala Gly Gln Arg Leu Lys Val Asp Phe Ala Leu Tyr Gly Gly Gly Val  
 115 120 125  
 Pro Gly Asn Leu Pro Glu Ile Arg Lys Met His Asp Ala Gly Ala Val  
 130 135 140  
 Gly Phe Lys Ser Met Met Ala Ala Ser Val Pro Gly Met Phe Asp Ala  
 145 150 155 160  
 Val Ser Asp Gly Glu Leu Phe Glu Ile Phe Gln Glu Ile Ala Ala Cys  
 165 170 175  
 Gly Ser Val Val Val Val His Ala Glu Asn Glu Thr Ile Ile Gln Ala  
 180 185 190  
 Leu Gln Lys Gln Ile Lys Ala Ala Gly Arg Lys Asp Met Ala Ala Tyr  
 195 200 205  
 Glu Ala Ser Gln Pro Val Phe Gln Glu Asn Glu Ala Ile Gln Arg Ala  
 210 215 220  
 Leu Leu Leu Gln Lys Glu Ala Gly Cys Arg Leu Ile Val Leu His Val  
 225 230 235 240  
 Ser Asn Pro Asp Gly Val Glu Leu Ile His Gln Ala Gln Ser Glu Gly  
 245 250 255  
 Gln Asp Val His Cys Glu Ser Gly Pro Gln Tyr Leu Asn Ile Thr Thr  
 260 265 270  
 Asp Asp Ala Glu Arg Ile Gly Pro Tyr Met Lys Val Ala Pro Pro Val  
 275 280 285  
 Arg Ser Ala Glu Met Asn Val Arg Leu Trp Glu Gln Leu Glu Asn Gly  
 290 295 300  
 Leu Ile Asp Thr Leu Gly Ser Asp His Gly Gly His Pro Val Glu Asp  
 305 310 315 320  
 Lys Glu Pro Gly Trp Lys Asp Val Trp Lys Ala Gly Asn Gly Ala Leu  
 325 330 335  
 Gly Leu Glu Thr Ser Leu Pro Met Met Leu Thr Asn Gly Val Asn Lys  
 340 345 350  
 Gly Arg Leu Ser Leu Glu Arg Leu Val Glu Val Met Cys Glu Lys Pro  
 355 360 365

Ala Lys Leu Phe Glu Ile Tyr Pro Gln Lys Gly Thr Leu Gln Val Gly  
 370 375 380

Ser Asp Ala Asp Leu Leu Ile Leu Asp Leu Asp Ile Asp Thr Lys Val  
 385 390 395 400

Asp Ala Ser Gln Phe Arg Ser Leu His Lys Tyr Ser Pro Phe Asp Gly  
 405 410 415

Met Pro Val Thr Gly Ala Pro Val Leu Thr Met Val Arg Gly Thr Val  
 420 425 430

Val Ala Glu Lys Gly Glu Val Leu Val Glu Gln Gly Phe Gly Gln Phe  
 435 440 445

Val Thr Arg His Asp Tyr Glu Ala Ser Lys  
 450 455 458

## (2) INFORMATION FOR SEQ ID NO: 11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1377 nucleotides
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: nucleic acid

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 11

atgtttgacg taatagttaa gaactgccgt atggtgtcca gcgacggaat caccgaggca	60
gacattctgg tgaaagacgg caaagtcgcc gcaatcagct cggacacaag tgatgttgag	120
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat	180
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat	240
tctgcggccg tgggaggcat caccaccatc atcgagatgc cgtaacctt cccgcccacc	300
accactttgg acgccttcct cgaaaagaag aagcaggcgg ggcagcggtt gaaagttgac	360
ttcgcgctct atggcggtgg agtgccggga aacctgccc agatccgcaa aatgcacgac	420
gccggcgacg tgggcttcaa gtcaatgatg gcagcctcag ttccgggcat gttcgacgcc	480
gtcagcgacg gcgaactgtt cgaaatcttc caggagatcg cagcctgtgg ttcagtcgcc	540
gtgggtccatg ccgagaatga aacgatcatt caagcgctcc agaagcagat caaagccgct	600
ggtcgcaagg acatggccgc ctacgaggca tcccaaccag ttttcagga gaacgaggcc	660
attcagcgtg cgttactact gcagaaagaa gccggctgtc gactgattgt gcttcacgtg	720



```

agcaaccctg acgggggtcga gctgatacat cgggcgcaat ccgagggcca ggacgtccac      780
tgcgagtcgg gtccgcagta tctgaatata accacggacg acgccgaacg aatcggaccg      840
tatatgaagg tcgcgccgcc cgtccgctca gccgagatga acgtcagatt atgggaacaa      900
cttgagaacg ggctcatcga cacccttggg tcagaccacg gcggacatcc tgtcgaggac      960
aaagaacccg gctggaagga cgtgtggaaa gccggcaacg gtgcgctggg ccttgagaca     1020
tccctgccta tgatgctgac caacggagtg aataaaggca ggctatcctt ggaacgcctc     1080
gtcgaggtga tgtgcgagaa acctgcgaag ctctttggca tctatccgca gaagggcacg     1140
ctacaggttg gttccgacgc cgatctgctc atcctcgatc tggatattga caccaaagtg     1200
gatgcctcgc agttccgac cctgcataag tacagcccgt tcgacgggat gcccgtcacg     1260
ggtgcacccg ttctgacgat ggtgcgcgga acggtggtgg cagagaaggg agaagttctg     1320
gtcgagcagg gattcggcca gttcgtcacc cgtcacgact acgaggcgtc gaagtga       1377

```

## (2) INFORMATION FOR SEQ ID NO: 12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 12

```

Met Phe Asp Val Ile Val Lys Asn Cys Arg Met Val Ser Ser Asp Gly
      5              10              15
Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile
      20              25              30
Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly
      35              40              45
Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile
      50              55              60
Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu
      65              70              75              80
Ser Ala Ala Val Gly Gly Ile Thr Thr Ile Ile Glu Met Pro Leu Thr
      85              90              95
Phe Pro Pro Thr Thr Thr Leu Asp Ala Phe Leu Glu Lys Lys Lys Gln
      100             105             110

```

Ala Gly Gln Arg Leu Lys Val Asp Phe Ala Leu Tyr Gly Gly Gly Val  
 115 120 125  
 Pro Gly Asn Leu Pro Glu Ile Arg Lys Met His Asp Ala Gly Ala Val  
 130 135 140  
 Gly Phe Lys Ser Met Met Ala Ala Ser Val Pro Gly Met Phe Asp Ala  
 145 150 155 160  
 Val Ser Asp Gly Glu Leu Phe Glu Ile Phe Gln Glu Ile Ala Ala Cys  
 165 170 175  
 Gly Ser Val Ala Val Val His Ala Glu Asn Glu Thr Ile Ile Gln Ala  
 180 185 190  
 Leu Gln Lys Gln Ile Lys Ala Ala Gly Arg Lys Asp Met Ala Ala Tyr  
 195 200 205  
 Glu Ala Ser Gln Pro Val Phe Gln Glu Asn Glu Ala Ile Gln Arg Ala  
 210 215 220  
 Leu Leu Leu Gln Lys Glu Ala Gly Cys Arg Leu Ile Val Leu His Val  
 225 230 235 240  
 Ser Asn Pro Asp Gly Val Glu Leu Ile His Arg Ala Gln Ser Glu Gly  
 245 250 255  
 Gln Asp Val His Cys Glu Ser Gly Pro Gln Tyr Leu Asn Ile Thr Thr  
 260 265 270  
 Asp Asp Ala Glu Arg Ile Gly Pro Tyr Met Lys Val Ala Pro Pro Val  
 275 280 285  
 Arg Ser Ala Glu Met Asn Val Arg Leu Trp Glu Gln Leu Glu Asn Gly  
 290 295 300  
 Leu Ile Asp Thr Leu Gly Ser Asp His Gly Gly His Pro Val Glu Asp  
 305 310 315 320  
 Lys Glu Pro Gly Trp Lys Asp Val Trp Lys Ala Gly Asn Gly Ala Leu  
 325 330 335  
 Gly Leu Glu Thr Ser Leu Pro Met Met Leu Thr Asn Gly Val Asn Lys  
 340 345 350  
 Gly Arg Leu Ser Leu Glu Arg Leu Val Glu Val Met Cys Glu Lys Pro  
 355 360 365  
 Ala Lys Leu Phe Glu Ile Tyr Pro Gln Lys Gly Thr Leu Gln Val Gly  
 370 375 380  
 Ser Asp Ala Asp Leu Leu Ile Leu Asp Leu Asp Ile Asp Thr Lys Val  
 385 390 395 400  
 Asp Ala Ser Gln Phe Arg Ser Leu His Lys Tyr Ser Pro Phe Asp Gly  
 405 410 415

Met Pro Val Thr Gly Ala Pro Val Leu Thr Met Val Arg Gly Thr Val  
                   420                  425                  430

Val Ala Glu Lys Gly Glu Val Leu Val Glu Gln Gly Phe Gly Gln Phe  
                   435                  440                  445

Val Thr Arg His Asp Tyr Glu Ala Ser Lys  
           450                  455                  458

## (2) INFORMATION FOR SEQ ID NO: 13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1377 nucleotides
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: nucleic acid

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 13

atgtttgacg taatagttaa gaactgccgt atggtgtcca gcgacggaat caccgaggca	60
gacattcttg tgaaagacgg caaagtcgcc gcaatcagct cggacacaag tgatgttgag	120
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat	180
gcgagccgaa ccattgacgc ggggtggcaag ttcgtgatgc cgggcgtggt cgatgaacat	240
tctgcggccg tgggaggcat caccaccatc atcgagatgc cgtttacctt cccgccacc	300
accacttttg acgccttctt cgaaaagaag aagcaggcgg ggcagcggtt gaaagttgac	360
ttcgcgctct atggcggtgg agtgccggga aacctgccc agatccgcaa aatgcacgac	420
gccggcgacg tgggcttcaa gtcaatgatg gcagcctcag ttccgggcat gttcgacgcc	480
gtcagcgacg gcgaactgtt cgaaatcttc caggagatcg cagcctgtgg ttcagtcgcc	540
gtggtccatg ccgagaatga aacgatcatt caagcgctcc agaagcagat caaagccgct	600
ggtcgcaagg acatggccgc ctacgaggca tccaaccag ttttcagga gaacgaggcc	660
attcagcgtg cgttactact gcagaaagaa gccggctgtc gactgattgt gcttcacgtg	720
agcaaccctg acggggtcga gctgatacat cgggcgcaat ccgagggccca ggacgtccac	780
tgcgagtcgg gtccgcagta tctgaatatc accacggacg acgccgaacg aatcggaccg	840
tatatgaagg tcgcgccgcc cgtccgctca gccgagatga acgtcagatt atgggaacaa	900
cttgagaacg ggctcatcga cacccttggg tcagaccacg gcggacatcc tgtcgaggac	960
aaagaacccg gctggaagga cgtgtggaaa gccggcaacg gtgcgctggg cttgagaca	1020

```

tccctgccta tgatgctgac caacggagtg aataaaggca ggctatcctt ggaacgcctc      1080
gtcgagggtga tgtgcgagaa acctgcgaag ctctttggca tctatccgca gaagggcacg      1140
ctacagggttg gttccgacgc cgatctgctc atcctcgatc tggatattga caccaaagtg      1200
gatgcctcgc agttccgac cctgcataag tacagcccgt tcgacgggat gcccgtcacg      1260
ggtgcaccgg ttctgacgat ggtgcgcgga acggtggtgg cagagaaggg agaagttctg      1320
gtcgagcagg gattcggcca gttcgtcacc cgtcacgact acgaggcgtc gaagtga      1377

```

## (2) INFORMATION FOR SEQ ID NO: 14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 14

```

Met Phe Asp Val Ile Val Lys Asn Cys Arg Met Val Ser Ser Asp Gly
      5              10              15
Ile Thr Glu Ala Asp Ile Leu Val Lys Asp Gly Lys Val Ala Ala Ile
      20              25              30
Ser Ser Asp Thr Ser Asp Val Glu Ala Ser Arg Thr Ile Asp Ala Gly
      35              40              45
Gly Lys Phe Val Met Phe Gly Val Val Asp Glu His Val His Ile Ile
      50              55              60
Asp Met Asp Leu Lys Asn Arg Tyr Gly Arg Phe Glu Leu Asp Ser Glu
      65              70              75              80
Ser Ala Ala Val Gly Gly Ile Thr Thr Ile Ile Glu Met Pro Phe Thr
      85              90              95
Phe Pro Pro Thr Thr Thr Leu Asp Ala Phe Leu Glu Lys Lys Lys Gln
      100             105             110
Ala Gly Gln Arg Leu Lys Val Asp Phe Ala Leu Tyr Gly Gly Gly Val
      115             120             125
Pro Gly Asn Leu Pro Glu Ile Arg Lys Met His Asp Ala Gly Ala Val
      130             135             140
Gly Phe Lys Ser Met Met Ala Ala Ser Val Pro Gly Met Phe Asp Ala
      145             150             155             160

```

Val Ser Asp Gly Glu Leu Phe Glu Ile Phe Gln Glu Ile Ala Ala Cys  
 165 170 175  
 Gly Ser Val Ala Val Val His Ala Glu Asn Glu Thr Ile Ile Gln Ala  
 180 185 190  
 Leu Gln Lys Gln Ile Lys Ala Ala Gly Arg Lys Asp Met Ala Ala Tyr  
 195 200 205  
 Glu Ala Ser Gln Pro Val Phe Gln Glu Asn Glu Ala Ile Gln Arg Ala  
 210 215 220  
 Leu Leu Leu Gln Lys Glu Ala Gly Cys Arg Leu Ile Val Leu His Val  
 225 230 235 240  
 Ser Asn Pro Asp Gly Val Glu Leu Ile His Arg Ala Gln Ser Glu Gly  
 245 250 255  
 Gln Asp Val His Cys Glu Ser Gly Pro Gln Tyr Leu Asn Ile Thr Thr  
 260 265 270  
 Asp Asp Ala Glu Arg Ile Gly Pro Tyr Met Lys Val Ala Pro Pro Val  
 275 280 285  
 Arg Ser Ala Glu Met Asn Val Arg Leu Trp Glu Gln Leu Glu Asn Gly  
 290 295 300  
 Leu Ile Asp Thr Leu Gly Ser Asp His Gly Gly His Pro Val<sup>\*</sup> Glu Asp  
 305 310 315 320  
 Lys Glu Pro Gly Trp Lys Asp Val Trp Lys Ala Gly Asn Gly Ala Leu  
 325 330 335  
 Gly Leu Glu Thr Ser Leu Pro Met Met Leu Thr Asn Gly Val Asn Lys  
 340 345 350  
 Gly Arg Leu Ser Leu Glu Arg Leu Val Glu Val Met Cys Glu Lys Pro  
 355 360 365  
 Ala Lys Leu Phe Glu Ile Tyr Pro Gln Lys Gly Thr Leu Gln Val Gly  
 370 375 380  
 Ser Asp Ala Asp Leu Leu Ile Leu Asp Leu Asp Ile Asp Thr Lys Val  
 385 390 395 400  
 Asp Ala Ser Gln Phe Arg Ser Leu His Lys Tyr Ser Pro Phe Asp Gly  
 405 410 415  
 Met Pro Val Thr Gly Ala Pro Val Leu Thr Met Val Arg Gly Thr Val  
 420 425 430  
 Val Ala Glu Lys Gly Glu Val Leu Val Glu Gln Gly Phe Gly Gln Phe  
 435 440 445  
 Val Thr Arg His Asp Tyr Glu Ala Ser Lys  
 450 455 458

## (2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 nucleotides
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 15

agaacatatg ttgacgtaa tagttaagaa

30

## (2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 28 nucleotides
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 16

aaaaggatcc tcacttcgac gcctcgta

28

## (2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 nucleotides
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 17

aggcgacata tgaccctgca gaaagcgcaa

30

## (2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 nucleotides
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 18

atgggatccc cggtaagtg ccttcattac

30

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/08159

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : Please See Extra Sheet. US CL : 435/231, 320.1, 252.3, 106, 116; 536/23.2 According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/231, 320.1, 252.3, 106, 116; 536/23.2  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN search terms: hydantoinase														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	Database GenBank on US National Center for Biotechnology Information, (Bethesda, MD, USA), No. P81006. MAY et al. 'D-Hydantoinase (Dihydropyrimidinase),' 15 July 1998.  MAY et al. Substrate-dependent enantioselectivity of a novel hydantoinase from <i>Arthrobacter aureescens</i> DSM 3745. <i>Journal of Biotechnology</i> . 26 March 1998, Vol. 61(1), pages 1-13.  GROSS et al. Production of L-tryptophan from D,L-5-indolymethylhydantoin by resting cells of a mutant of <i>Arthrobacter</i> species (DSM 3747). <i>Journal of Biotechnology</i> . 1990, Vol. 14, pages 363-376.	1												
Y		1-34												
Y		1-34												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*E* earlier document published on or after the international filing date</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*A* document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 12 JUNE 2000		Date of mailing of the international search report 18 JUL 2000												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized Officer KATHLEEN KERR Telephone No. (703) 308-0198												



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/08159

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WAGNER et al. Production of L-methionine from D,L-5-(2-methylthioethyl)hydantoin by resting cells of a new mutant strain of <i>Arthrobacter</i> species DSM 7330. <i>Journal of Biotechnology</i> . 1996, Vol. 46, pages 63-68.	1-34
A,P	SYLDATK et al. Microbial hydantoinases - industrial enzymes from the origin of life? <i>Appl Microbiol Biotechnol</i> . 1999, Vol. 51, pages 293-309.	1-34
A	KIM et al. Identification of the structural similarity in the functionality related amidohydrolases acting on the cyclic amide ring. <i>Biochemical Journal</i> . 1998, Vol. 330, pages 295-302.	1-34
A	MAY et al. Molecular Evolution of Hydantoinases. <i>Biological Chemistry</i> . June 1998, Vol. 379, pages 743-747.	1-34
A	BOMMARIUS et al. Biocatalysis to amino acid-based chiral pharmaceuticals-examples and perspectives. <i>Journal of Molecular Catalysis B: Enzymatic</i> 5. 1998, pages 1-11.	1-34
A	OGAWA et al. Diversity and versatility of microbial hydantoin-transforming enzymes. <i>Journal of Molecular Catalysis B: Enzymatic</i> 2. 1997, pages 163-176.	1-34

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/08159

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (7):

C12N 9/86, 15/00, 15/09, 15/63, 15/70, 15/74, 1/20; C12P 13/04, 13/06; C07H 21/04

## BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

### 2. Where no meaningful search could be carried out, specifically:

Claim 1 contains an obvious error. The unmodified hydantoinase sequence should recite an amino acid sequence (SEQ ID NO: 2), not a polynucleotide sequence (SEQ ID NO: 1) as written. A similar error is noted in Claim 10 which should recite a nucleic acid segment which encodes an unmodified hydantoinase as an amino acid sequence (SEQ ID NO: 2), not a polynucleotide sequence (SEQ ID NO: 1) as written. The Authorized Officer of the Searching Authority will search claims 1 and 10, and their dependent claims, as if the claims both refer to the amino acid sequence (SEQ ID NO: 2).

Claim 7 is unsearchable because the amino acid sequence, SEQ ID NO: 2, which is the unmodified hydantoinase enzyme sequence, has a glutamate residue, not a valine residue, at position 255; the particular mutation requested by applicants is Val255 to an Ala residue. Thus, it is unclear whether applicants' claim is to modifications at position 255 or at a neighboring position which is a valine residue. Claims 1, 2, 10-34, as they pertain to modifications at Val255, were also not searched.